ArticleNeuroImage. Clinical2021
Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial.
Article in NeuroImage. Clinical, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Fast Submillimeter Whole-Brain TMagnetic resonance in medicine · 2026Article
- Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.Neurology · 2026Observational
- Complex Deep Neural Networks for Denoising Ultra-Fast Submillimeter T2*-weighted Imaging and Quantitative Susceptibility Mapping.European journal of radiology artificial intelligence · 2026Article
- Diagnostic performance of central vein sign and paramagnetic rim lesion integration for multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Comparison of central FLAIR hypointensity and central vein sign on FLAIR* in a diagnostic cohort.European journal of radiology · 2026Article
- Investigating the Frequency and Outcome of Central Vein Sign and Paramagnetic Rim Lesions in Children With MOGAD.Neurology · 2026Article
- Diagnostic Accuracy of Isotropic FLAIR-T2* Fusion Imaging for Central Vein Sign Detection in Multiple Sclerosis: a Comparative Study at 1.5 T and 3 T.Clinical neuroradiology · 2025Observational
- Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic.Neurology · 2025Observational
- The Kappa Free Light Chains Index and Central Vein Sign: Two New Biomarkers for Multiple Sclerosis Diagnosis.Neurology and therapy · 2025Review
- Automated segmentation of multiple sclerosis lesions, paramagnetic rims, and central vein sign on MRI provides reliable diagnostic biomarkers.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Incorporation of the central vein sign into the McDonald criteria.Multiple sclerosis and related disorders · 2025Article
- Unexpected Low Rate of Amyloid-β Pathology in Multiple Sclerosis Patients.Annals of neurology · 2024Article
- Diagnostic performance of central vein sign versus oligoclonal bands for multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Central Vein Sign, Cortical Lesions, and Paramagnetic Rim Lesions for the Diagnostic and Prognostic Workup of Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2024Observational
- The use of 7T MRI in multiple sclerosis: review and consensus statement from the North American Imaging in Multiple Sclerosis Cooperative.Brain communications · 2024Review
- A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- How Early Is Early Multiple Sclerosis?Journal of clinical medicine · 2023Review
- Emerging imaging and liquid biomarkers in multiple sclerosis.European journal of immunology · 2023Review
- Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective.Journal of neurology · 2023Review
- Neurodegeneration in multiple sclerosis.WIREs mechanisms of disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
The specificity and implementation of current MRI-based diagnostic criteria for multiple sclerosis (MS) are imperfect. Approximately 1 in 5 of individuals diagnosed with MS are eventually determined not to have the disease, with overreliance on MRI findings a major cause of MS misdiagnosis. The central vein sign (CVS), a proposed MRI biomarker for MS lesions, has been extensively studied in numerous cross sectional studies and may increase diagnostic specificity for MS. CVS has desirable analytical, measurement, and scalability properties. "Central Vein Sign: A Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS)" is an NIH-supported, 2-year, prospective, international, multicenter study conducted by the North American Imaging in MS Cooperative (NAIMS) to evaluate CVS as a diagnostic biomarker for immediate translation into clinical care. Study objectives include determining the concordance of CVS and McDonald Criteria to diagnose MS, the sensitivity of CVS to detect MS in those with typical presentations, and the specificity of CVS among those with atypical presentations. The study will recruit a total of 400 participants (200 with typical and 200 with atypical presentations) across 11 sites. T2*-weighted, high-isotropic-resolution, segmented echo-planar MRI will be acquired at baseline and 24 months on 3-tesla scanners, and FLAIR* images (combination of FLAIR and T2*) will be generated for evaluating CVS. Data will be processed on a cloud-based platform that contains clinical and CVS rating modules. Imaging quality control will be conducted by automated methods and neuroradiologist review. CVS will be determined by Select6* and Select3* lesion methods following published criteria at each site and by central readers, including neurologists and neuroradiologists. Automated CVS detection and algorithms for incorporation of CVS into McDonald Criteria will be tested. Diagnosis will be adjudicated by three neurologists who served on the 2017 International Panel on the Diagnosis of MS. The CAVS-MS study aims to definitively establish CVS as a diagnostic biomarker that can be applied broadly to individuals presenting for evaluation of the diagnosis of MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.